Lexicon Stock Today

LXRX
 Stock
  

USD 2.13  0.09  4.05%   

Market Performance
0 of 100
Odds Of Distress
Less than 48
Lexicon Pharmaceutcl is trading at 2.13 as of the 26th of November 2022; that is -4.05 percent decrease since the beginning of the trading day. The stock's open price was 2.22. Lexicon Pharmaceutcl has 48 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Lexicon Pharmaceutcl are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2022 and ending today, the 26th of November 2022. Click here to learn more.
CUSIP
528872104
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of April 2000
Category
Healthcare
Classification
Health Care
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceutcl operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 188.73 M outstanding shares of which 4.26 M shares are now shorted by private and institutional investors with about 8.4 trading days to cover. More on Lexicon Pharmaceutcl

Moving together with Lexicon Pharmaceutcl

+0.63DOOOBRP Inc Earnings Call  This WeekPairCorr

Moving against Lexicon Pharmaceutcl

-0.77SGMLSigma Lithium Corp Buyout TrendPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Lexicon Pharmaceutcl Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Lexicon Pharmaceutcl's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Lexicon Pharmaceutcl or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Lexicon Pharmaceutcl generated a negative expected return over the last 90 days
Lexicon Pharmaceutcl has high historical volatility and very poor performance
The company reported the previous year's revenue of 125 K. Net Loss for the year was (97.06 M) with loss before overhead, payroll, taxes, and interest of (54.75 M).
Lexicon Pharmaceutcl currently holds about 136.2 M in cash with (90.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72.
Over 82.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: The Global Clinical Diagnostics Market is expected to Surge at a CAGR of 7.02 percent During the Forecast Period DelveInsight - Yahoo Finance
CEO and President and DirectorLonnel Coats
Average Analyst Recommendation
Analysts covering Lexicon Pharmaceutcl report their recommendations after researching Lexicon Pharmaceutcl's financial statements, talking to executives and customers, or listening in on Lexicon Pharmaceutcl's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Lexicon Pharmaceutcl. The Lexicon consensus assessment is calculated by taking the average forecast from all of the analysts covering Lexicon Pharmaceutcl.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Lexicon Pharmaceutcl based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Lexicon Pharmaceutcl financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted115.4 M145.7 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares115 M145.7 M
Significantly Down
Increasing
Slightly volatile
Return on Average Assets(52.87)(51.5167)
Fairly Down
Decreasing
Very volatile
Net Cash Flow from Operations(93.9 M)(87 M)
Significantly Down
Decreasing
Very volatile
Current Liabilities22.7 M22.1 M
Fairly Up
Increasing
Stable
Total Liabilities23.9 M23.3 M
Fairly Up
Decreasing
Very volatile
Gross Margin111106
Notably Up
Increasing
Slightly volatile
Total Debt13.7 M13.4 M
Fairly Up
Increasing
Stable
Asset Turnover0.00180.0017
Fairly Up
Increasing
Stable
Current Assets91.3 M88.9 M
Fairly Up
Decreasing
Slightly volatile
Total Assets140.5 M136.9 M
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Lexicon Pharmaceutcl's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Lexicon Pharmaceutcl's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Lexicon Pharmaceutcl's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lexicon Pharmaceutcl's financial leverage. It provides some insight into what part of Lexicon Pharmaceutcl's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Lexicon Pharmaceutcl's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Lexicon Pharmaceutcl deploys its capital and how much of that capital is borrowed.
Liquidity
Lexicon Pharmaceutcl cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 30.63 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Lexicon Pharmaceutcl has a current ratio of 7.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Lexicon Pharmaceutcl until it has trouble settling it off, either with new capital or with free cash flow. So, Lexicon Pharmaceutcl's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lexicon Pharmaceutcl sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lexicon to invest in growth at high rates of return. When we think about Lexicon Pharmaceutcl's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(93.89 Million)
Lexicon Pharmaceutcl (LXRX) is traded on NASDAQ Exchange in USA and employs 87 people. The company currently falls under 'Small-Cap' category with current market capitalization of 413.31 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lexicon Pharmaceutcl's market, we take the total number of its shares issued and multiply it by Lexicon Pharmaceutcl's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Lexicon Pharmaceutcl conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 188.73 M outstanding shares of which 4.26 M shares are now shorted by private and institutional investors with about 8.4 trading days to cover. Lexicon Pharmaceutcl currently holds about 136.2 M in cash with (90.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72.
Check Lexicon Pharmaceutcl Probability Of Bankruptcy
Ownership
Lexicon Pharmaceutcl maintains a total of one hundred eighty-eight million seven hundred thirty thousand outstanding shares. The majority of Lexicon Pharmaceutcl outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Lexicon Pharmaceutcl to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Lexicon Pharmaceutcl. Please pay attention to any change in the institutional holdings of Lexicon Pharmaceutcl as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Lexicon Ownership Details

Lexicon Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Lexicon Pharmaceutcl jumping above the current price in 90 days from now is about 79.6%. The Lexicon Pharmaceutcl probability density function shows the probability of Lexicon Pharmaceutcl stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.6791. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Lexicon Pharmaceutcl will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Lexicon Pharmaceutcl is significantly underperforming DOW.
  Odds Below 2.13HorizonTargetOdds Above 2.13
20.31%90 days
 2.13 
79.60%
Based on a normal probability distribution, the odds of Lexicon Pharmaceutcl to move above the current price in 90 days from now is about 79.6 (This Lexicon Pharmaceutcl probability density function shows the probability of Lexicon Stock to fall within a particular range of prices over 90 days) .

Lexicon Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Lexicon Pharmaceutcl that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lexicon Pharmaceutcl's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lexicon Pharmaceutcl's value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares12.7 K24 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares12.7 K27 K
View Lexicon Pharmaceutcl Diagnostics

Lexicon Pharmaceutcl Historical Income Statement

Lexicon Pharmaceutcl Income Statement is one of the three primary financial statements used for reporting Lexicon's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Lexicon Pharmaceutcl revenue and expense. Lexicon Pharmaceutcl Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Lexicon Pharmaceutcl Direct Expenses is fairly stable at the moment as compared to the past year. Lexicon Pharmaceutcl reported Direct Expenses of 1.74 Million in 2021. Cost of Revenue is likely to rise to about 2.5 M in 2022, whereas Consolidated Income is likely to drop (94.7 M) in 2022. View More Fundamentals

Lexicon Stock Against Markets

Picking the right benchmark for Lexicon Pharmaceutcl stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Lexicon Pharmaceutcl stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Lexicon Pharmaceutcl is critical whether you are bullish or bearish towards Lexicon Pharmaceutcl at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lexicon Pharmaceutcl without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module

Lexicon Pharmaceutcl Corporate Directors

Lexicon Pharmaceutcl corporate directors refer to members of a Lexicon Pharmaceutcl board of directors. The board of directors generally takes responsibility for the Lexicon Pharmaceutcl's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Lexicon Pharmaceutcl's board members must vote for the resolution. The Lexicon Pharmaceutcl board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Samuel Barker - Independent DirectorProfile
Robert Lefkowitz - Independent DirectorProfile
Christopher Sobecki - Independent DirectorProfile
Alan Nies - Independent DirectorProfile

Invested in Lexicon Pharmaceutcl?

The danger of trading Lexicon Pharmaceutcl is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Lexicon Pharmaceutcl is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Lexicon Pharmaceutcl. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Lexicon Pharmaceutcl is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Correlation Analysis. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for analysis

When running Lexicon Pharmaceutcl price analysis, check to measure Lexicon Pharmaceutcl's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceutcl is operating at the current time. Most of Lexicon Pharmaceutcl's value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceutcl's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lexicon Pharmaceutcl's price. Additionally, you may evaluate how the addition of Lexicon Pharmaceutcl to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Lexicon Pharmaceutcl's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceutcl. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceutcl listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
(0.63) 
Market Capitalization
402 M
Quarterly Revenue Growth YOY
0.7
Return On Assets
(0.33) 
Return On Equity
(0.69) 
The market value of Lexicon Pharmaceutcl is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceutcl's value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceutcl's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceutcl's market value can be influenced by many factors that don't directly affect Lexicon Pharmaceutcl's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceutcl's value and its price as these two are different measures arrived at by different means. Investors typically determine Lexicon Pharmaceutcl value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceutcl's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.